Page 15 of 17 SEC Filing
Pursuant to Rule 13d-2 promulgated under the U.S. Securities Exchange Act of 1934, as amended
(the Exchange Act), this Schedule 13D/A (this Amendment No. 15) amends and supplements the Schedule 13D filed on November 24, 2010 (the Original Schedule 13D, as amended and supplemented by the Schedule 13D/A
filed on December 13, 2010, the Schedule 13D/A filed on December 17, 2010, the Schedule 13D/A filed on March 3, 2011, the Schedule 13D/A filed on May 26, 2011, the Schedule 13D/A filed on May 31, 2011, the Schedule 13D/A
filed on December 13, 2011, the Schedule 13D/A filed on December 19, 2011, the Schedule 13D/A filed on June 5, 2012, the Schedule 13D/A filed on May 1, 2013, the Schedule 13D/A filed on May 15, 2013, the Schedule 13D/A filed on
March 4, 2014, the Schedule 13D/A filed on June 11, 2015, the Schedule 13D/A filed on June 16, 2015 and the Schedule 13D/A filed on March 3, 2016, together with this Amendment No. 15, the Schedule 13D), and is being filed
on behalf of WP X Biologics LLC, a Delaware limited liability company (WP X B), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership (WP X), and holder of 96.9% of the equity interest in WP X B, Warburg
Pincus X Partners, L.P., a Delaware limited partnership and holder of 3.1% of the equity interest in WP X B (WPP X, and together with WP X, the Funds), Warburg Pincus X, L.P., a Delaware limited partnership (WP X
LP), and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership (WP X GP), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company (WPP GP), and
the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership (WP Partners), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company (WPP GP
LLC), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company (WP), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company (WP
LLC), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a Warburg Pincus
Reporting Person and collectively, the Warburg Pincus Reporting Persons). Messrs. Kaye and Landy may be deemed to control the Funds and WP X B, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. This Amendment No. 15
relates to the common stock, $0.0001 par value per share (the Shares), of China Biologic Products, Inc., a Delaware corporation (the Company).
All capitalized terms used herein which are not defined herein have the meanings given to such terms in the Original Schedule 13D, as
amended.
Item 4. Purpose of Transaction
Item 4 of the Schedule 13D is hereby supplemented by inserting
the following after the last paragraph thereof:
On March 4, 2016, the Underwriter notified the Funds of its election to exercise the
option to purchase additional Shares from the Funds in full.
On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the
Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.
Item 5. Interest in the Securities of the Issuer
Item 5 of the Schedule 13D is hereby amended
and restated in its entirety as follows:
(a) The percentages used herein are calculated based upon 26,590,974 Shares outstanding as of
February 25, 2016, as reported in the Companys Form 10-K for the year ended December 31, 2015, filed with the SEC on February 25, 2016.
WP X B is the direct owner of 3,112,920 Shares representing approximately 11.7% of the outstanding Shares of the Company. As WP X B is owned
96.9% by WP X and 3.1% by WPP X, therefore, WP X is deemed to beneficially own 3,960,496 Shares representing 14.9% of the outstanding Shares, including 944,077 Shares that it directly holds, and WPP X is deemed to beneficially own 126,704 Shares
representing 0.5% of the outstanding Shares, including 30,203 Shares that it directly holds.
(b) WP X B is deemed to (i) share voting
power and disposition power over 3,016,419 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X) and (ii) share voting power and disposition power over 96,501 Shares with each of the Warburg Pincus Reporting Persons (other than
WP X). WP X is deemed to (i) share voting power and disposition power over 3,016,419 Shares with WP X B and (ii) share voting power and disposition power over 3,960,496 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X and
WP X B). WPP X is deemed to (i) share voting power and disposition power over 96,501 Shares with WP X B and (ii) share voting and disposition power over 126,704 Shares with each of the Warburg Pincus Reporting Persons (other than WP X and WP X B).
Each of the Warburg Pincus Reporting Persons (other than the Funds and WP X B) is deemed to (i) share voting power and disposition power over 3,112,920 Shares with WP X B and (ii) share voting power and disposition power over 4,087,200 Shares
with the Funds.
Follow China Biologic Products Inc. (NASDAQ:CBPO)
Follow China Biologic Products Inc. (NASDAQ:CBPO)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Pursuant to Rule 13d-2 promulgated under the U.S. Securities Exchange Act of 1934, as amended
(the Exchange Act), this Schedule 13D/A (this Amendment No. 15) amends and supplements the Schedule 13D filed on November 24, 2010 (the Original Schedule 13D, as amended and supplemented by the Schedule 13D/A
filed on December 13, 2010, the Schedule 13D/A filed on December 17, 2010, the Schedule 13D/A filed on March 3, 2011, the Schedule 13D/A filed on May 26, 2011, the Schedule 13D/A filed on May 31, 2011, the Schedule 13D/A
filed on December 13, 2011, the Schedule 13D/A filed on December 19, 2011, the Schedule 13D/A filed on June 5, 2012, the Schedule 13D/A filed on May 1, 2013, the Schedule 13D/A filed on May 15, 2013, the Schedule 13D/A filed on
March 4, 2014, the Schedule 13D/A filed on June 11, 2015, the Schedule 13D/A filed on June 16, 2015 and the Schedule 13D/A filed on March 3, 2016, together with this Amendment No. 15, the Schedule 13D), and is being filed
on behalf of WP X Biologics LLC, a Delaware limited liability company (WP X B), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership (WP X), and holder of 96.9% of the equity interest in WP X B, Warburg
Pincus X Partners, L.P., a Delaware limited partnership and holder of 3.1% of the equity interest in WP X B (WPP X, and together with WP X, the Funds), Warburg Pincus X, L.P., a Delaware limited partnership (WP X
LP), and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership (WP X GP), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company (WPP GP), and
the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership (WP Partners), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company (WPP GP
LLC), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company (WP), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company (WP
LLC), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a Warburg Pincus
Reporting Person and collectively, the Warburg Pincus Reporting Persons). Messrs. Kaye and Landy may be deemed to control the Funds and WP X B, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. This Amendment No. 15
relates to the common stock, $0.0001 par value per share (the Shares), of China Biologic Products, Inc., a Delaware corporation (the Company).
All capitalized terms used herein which are not defined herein have the meanings given to such terms in the Original Schedule 13D, as
amended.
| Item 4. | Purpose of Transaction |
Item 4 of the Schedule 13D is hereby supplemented by inserting
the following after the last paragraph thereof:
On March 4, 2016, the Underwriter notified the Funds of its election to exercise the
option to purchase additional Shares from the Funds in full.
On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the
Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.
| Item 5. | Interest in the Securities of the Issuer |
Item 5 of the Schedule 13D is hereby amended
and restated in its entirety as follows:
(a) The percentages used herein are calculated based upon 26,590,974 Shares outstanding as of
February 25, 2016, as reported in the Companys Form 10-K for the year ended December 31, 2015, filed with the SEC on February 25, 2016.
WP X B is the direct owner of 3,112,920 Shares representing approximately 11.7% of the outstanding Shares of the Company. As WP X B is owned
96.9% by WP X and 3.1% by WPP X, therefore, WP X is deemed to beneficially own 3,960,496 Shares representing 14.9% of the outstanding Shares, including 944,077 Shares that it directly holds, and WPP X is deemed to beneficially own 126,704 Shares
representing 0.5% of the outstanding Shares, including 30,203 Shares that it directly holds.
(b) WP X B is deemed to (i) share voting
power and disposition power over 3,016,419 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X) and (ii) share voting power and disposition power over 96,501 Shares with each of the Warburg Pincus Reporting Persons (other than
WP X). WP X is deemed to (i) share voting power and disposition power over 3,016,419 Shares with WP X B and (ii) share voting power and disposition power over 3,960,496 Shares with each of the Warburg Pincus Reporting Persons (other than WPP X and
WP X B). WPP X is deemed to (i) share voting power and disposition power over 96,501 Shares with WP X B and (ii) share voting and disposition power over 126,704 Shares with each of the Warburg Pincus Reporting Persons (other than WP X and WP X B).
Each of the Warburg Pincus Reporting Persons (other than the Funds and WP X B) is deemed to (i) share voting power and disposition power over 3,112,920 Shares with WP X B and (ii) share voting power and disposition power over 4,087,200 Shares
with the Funds.
